Which Patients with Advanced CSCC Will Likely Benefit Most from PD1 Checkpoint Inhibition?

Which Patients with Advanced CSCC Will Likely Benefit Most from PD1 Checkpoint Inhibition?


Published

November 12, 2018

Created by

CMEducation Resources symposium

Related Presenters

Darrell Rigel, MS, MD

Darrell Rigel, MS, MD

Program ChairClinical Professor of DermatologyNew York Medical CenterNew York, NY